Publications en collaboration avec des chercheurs de Hospital Universitario Virgen del Rocío (82)

2023

  1. The Prognostic Significance of Tumor-Infiltrating Lymphocytes, PD-L1, BRCA Mutation Status and Tumor Mutational Burden in Early-Stage High-Grade Serous Ovarian Carcinoma-A Study by the Spanish Group for Ovarian Cancer Research (GEICO)

    International journal of molecular sciences, Vol. 24, Núm. 13

2022

  1. The Clonal Relationship Between the Ductal and Lobular Components of Mixed Ductal-Lobular Carcinomas Suggested a Ductal Origin in Most Tumors

    American Journal of Surgical Pathology, Vol. 46, Núm. 11, pp. 1545-1553

2020

  1. Low prevalence of HER2-positive breast carcinomas among screening detected breast cancers

    Cancers, Vol. 12, Núm. 6, pp. 1-16

  2. The Frequency and Prognostic Significance of the Histologic Type in Early-stage Ovarian Carcinoma: A Reclassification Study by the Spanish Group for Ovarian Cancer Research (GEICO)

    American Journal of Surgical Pathology, Vol. 44, Núm. 2, pp. 149-161

2019

  1. Clinical challenges and implications of intratumor heterogeneity

    Revista Espanola de Patologia, Vol. 52, Núm. 4, pp. 234-241

  2. Molecular basis of tumor heterogeneity in endometrial carcinosarcoma

    Cancers, Vol. 11, Núm. 7

2018

  1. Erratum to: Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology (Clinical and Translational Oncology, (2018), 20, 3, (274-285), 10.1007/s12094-017-1719-x)

    Clinical and Translational Oncology

  2. Proposal for the creation of a national strategy for precision medicine in cancer: a position statement of SEOM, SEAP, and SEFH

    Clinical and Translational Oncology, Vol. 20, Núm. 4, pp. 443-447

  3. Recommendations for biomarker testing in epithelial ovarian cancer. A national consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Revista Espanola de Patologia

  4. Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Clinical and Translational Oncology, Vol. 20, Núm. 3, pp. 274-285

2017

  1. Proposal for the Creation of a National Strategy for Precision Medicine in Cancer: A position statement of SEOM, SEAP and SEFH

    Farmacia Hospitalaria, Vol. 41, Núm. 6, pp. 688-691

2016

  1. CK19 expression in breast tumours and lymph node metastasis after neoadjuvant therapy

    Histopathology, Vol. 69, Núm. 2, pp. 239-249

  2. Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer

    Oncotarget, Vol. 7, Núm. 35, pp. 56295-56308

  3. Loss of the tumor suppressor spinophilin (PPP1R9B) increases the cancer stem cell population in breast tumors

    Oncogene, Vol. 35, Núm. 21, pp. 2777-2788

2015

  1. A role for the transducer of the Hippo pathway, TAZ, in the development of aggressive types of endometrial cancer

    Modern Pathology, Vol. 28, Núm. 11, pp. 1492-1503

  2. Nuclear TAZ expression associates with the triple-negative phenotype in breast cancer

    Endocrine-Related Cancer, Vol. 22, Núm. 3, pp. 443-454

2014

  1. A 9-protein biomarker molecular signature for predicting histologic type in endometrial carcinoma by immunohistochemistry

    Human Pathology, Vol. 45, Núm. 12, pp. 2394-2403

  2. A core microRNA signature associated with inducers of the epithelial-to-mesenchymal transition

    Journal of Pathology, Vol. 232, Núm. 3, pp. 319-329

  3. Identification of cellular and genetic drivers of breast cancer heterogeneity in genetically engineered mouse tumour models

    Journal of Pathology, Vol. 233, Núm. 2, pp. 124-137

  4. Prognostic relevance of estrogen receptor-α Ser167 phosphorylation in stage II-III colon cancer patients

    Human Pathology, Vol. 45, Núm. 12, pp. 2437-2446